More than 9 out of 10 patients benefitted from at least 1 IGA* grade improvement of their acne compared to 73% in the control (standard of care) at week (6) six1
There was a reduction of at least 40% in inflammatory acne lesion counts in 82% of patients compared to 46% in the control group at week 121
More than half of patients benefited from at least 2 IGA* grade improvements of their acne compared to 18% in the control group at week 121
92% of patients who benefitted from at least 2 IGA* grade improvements of their acne maintained their gains at week 242
Excellent compliance rate throughout lengthy 24-week long study period in young patient population (mean age: 22 years)2
Kleresca® Safety Profile
Kleresca® Treatments are not absorbed or metabolized by the skin and are considered to be a pleasant and comfortable experience by patients.
In clinical trials, Kleresca® showed high safety with no serious adverse events. All side effects were transient, nonpermanent and did not require any intervention by the clinic.